CD27/TNFRSF7
Alpha Lifetech can provide CD27/TNFRSF7 corresponding products, help each customer's research and development.
01
Introduction To CD27/TNFRSF7
Drug targets a biomolecule that can directly bind to drugs and then react. Generally, the target refers to a protein, which is related to the cause of disease. The focus of the target began with focusing on tumors and then began to spread to various fields. Introduction to CD27/TNFRSF7 protein is a common target in medicine.
CD27, a member of the TNF receptor superfamily, also known as TNFRSF7, is a transmembrane phosphoglycoprotein expressed on CD4 + and CD8 + T cells and constitutively expressed on naive T cells, memory B cells, NK cells, hematopoietic stem cells (HSC), and progenitor cells. Expression increases upon T cell activation and falls from the cell surface, and upon activation forms soluble CD27.
Function of Target CD27/TNFRSF7
As a member of the TNFR superfamily, CD27 is expressed in most T cells, CD27 signaling is controlled by its ligand CD70, and the CD27 – CD70 interaction provides a potent second signal for the initiation of CD4-dependent T cells and CD8-independent T cells during tumor clearance. The indirect killing mechanism mainly releases perforin and cytokines through the action of transmembrane glycoprotein (CD27) on NK cells and transmembrane glycoprotein (CD70) on NK cells, thus activating cytotoxic T lymphocytes (CTL) to further kill tumor cells. The interaction between CD27 and its ligand CD70 (also known as TNFSF7) provides a critical co-stimulatory signal for T cells. Activation of CD27 can promote T cell activation, proliferation, and differentiation, and subsequently enhance the immune response. CD27 is also involved in regulating the balance of the immune system, maintaining immune homeostasis by affecting the number and function of different T-cell subsets (e.g., effector T cells and regulatory T cells).
Gene Pathway of Target CD27/TNFRSF7
Upon binding of CD27 to its ligand CD70, it triggers a series of signaling events. This binding is specific, and CD70 exists as a trimeric form to bind to the three disulfide bridges of CD27. Upon binding to CD70, CD27 transmits a signal into the cell through the signal transduction domain in its cytoplasmic tail. These signals may include the recruitment and activation of the TRAF (TNF-related factors) family, which in turn trigger the activation of downstream signaling pathways. Activation of the CD27 signaling pathway ultimately leads to the production of a series of downstream effects, including T cell activation, proliferation, differentiation, and the production of cytokines. Together, these effects act on the target cells to generate a functional immune response.
Fig 1: CD27 Gene Pathway. (Reference source: Gong L, Luo J, Zhang Y, Yang Y, et al,. Nasopharyngeal carcinoma cells promote regulatory T-cell development and suppressive activity via CD70-CD27 interaction. Nat Commun. 2023 Apr 6;14(1):1912. )
Alpha Lifetech Can Provide
At present, various drugs targeting CD27/TNFRSF7 are constantly under development, and taking drugs alone or together with other products to treat diseases has become a new method and remarkable achievements have been made. CD27/TNFRSF7 protein has shown important research value and application prospects in tumor biology, and drug research and development. With further research and technological advances, CD27/TNFRSF7 protein products are also essential. Alpha Lifetech can provide CD27/TNFRSF7 corresponding products and help each customer's research and development. In addition, Alpha Lifetech can provide efficient and accurate EC50 / IC50, helping customer companies to screen compounds efficiently and accurately. At the same time, Alpha Lifetech also provides some services such as recombinant antibody production and recombinant antibody purification, to conduct in vitro affinity screening to ensure the maturity of recombinant antibody affinity and help customers in antibody drug discovery, and subsequent various experiments.
| Catalog Number | Product Name | Product Sizes |
|---|---|---|
| ALP64681 | 50ug,100ug,500ug | |
| ALP64605 | 50ug,100ug,500ug | |
| ADT1692 | 100ug,1mg,5mg | |
Reference
[1] Gong L, Luo J, Zhang Y, Yang Y, Li S, Fang X, Zhang B, Huang J, Chow LK, Chung D, Huang J, Huang C, Liu Q, Bai L, Tiu YC, Wu P, Wang Y, Tsao GS, Kwong DL, Lee AW, Dai W, Guan XY. Nasopharyngeal carcinoma cells promote regulatory T-cell development and suppressive activity via CD70-CD27 interaction. Nat Commun. 2023 Apr 6;14(1):1912.
[2] Jaeger-Ruckstuhl CA, Lo Y, Fulton E, Waltner OG, Shabaneh TB, Simon S, Muthuraman PV, Correnti CE, Newsom OJ, Engstrom IA, Kanaan SB, Bhise SS, Peralta JMC, Ruff R, Price JP, Stull SM, Stevens AR, Bugos G, Kluesner MG, Voillet V, Muhunthan V, Morrish F, Olson JM, Gottardo R, Sarthy JF, Henikoff S, Sullivan LB, Furlan SN, Riddell SR. Signaling via a CD27-TRAF2-SHP-1 axis during naive T cell activation promotes memory-associated gene regulatory networks. Immunity. 2024 Feb 13;57(2):287-302.e12.
[3] Grant EJ, Nüssing S, Sant S, Clemens EB, Kedzierska K. The role of CD27 in anti-viral T-cell immunity. Curr Opin Virol. 2017 Feb;22:77-88.
Video Resources
If you have any questions, please feel free to contact us at any time.
Leave Your Message
2018-07-16
0102